1 December 2016 in Oral Oncology
1 January 2017 in Otology & Neurotology
Objective: To evaluate the ability of ultra-high-field magnetic resonance imaging (UHF-MRI) at 11.7 T to visualize membranous structures of the human inner ear. Specimens: Three temporal bones were extracted from cadaveric human heads for use with small-bore UHF-MRI. Intervention: Ex vivo cadaveric temporal bone specimens were imaged using an 11.7 T magnetic resonance imaging (MRI) scanner via T1- and T2-weighted-imaging with and without contrast. Main Outcome Measure: Qualitative visualization of membranous components of the inner ear compared with reports of UHF-MRI at lower field strengths. Results: The membranous anatomy of the inner ear was superbly visualized at 11.7 T. In the cochlea, Reissner's membrane, the scala media, and the basilar membrane were clearly shown on the scan. In the vestibular labyrinth, the wedge-shaped crista ampullaris and the maculae of both the saccule and utricle were visible. Details of the endolymphatic sac and duct were also demonstrated. Conclusion: To our knowledge, this report presents the first images of the ex vivo human inner ear using 11.7 T UHF-MRI, offering near-histologic resolution. Increased field strength may be particularly useful when imaging the delicate membranous anatomy of the inner ear. Further research on the use of UHF-MRI in clinical and research settings could illuminate structural changes associated with inner ear disorders.
1 October 2016 in Oral Oncology
7 January 2016 in Annals of Otology, Rhinology & Laryngology
BVBrenda Capobres Villegas
Tracheoesophageal voice prostheses are invaluable for speech rehabilitation in patients who have received total laryngectomy, but device failure impedes communication and creates psychosocial and financial burdens. This study compares the Provox 2 and Provox Vega voice prostheses on the parameter of device life. This was a retrospective observational study of 21 patients with 181 device replacements at an academic tertiary care medical center. Disparity in device life and factors that may influence device life were analyzed. The mean device life for Provox 2, at 115.6 days (SE = 5.8), was longer than for Provox Vega, at 65.1 days (SE = 7.5) (P < .001). Device longevity was greater for Provox 2 over Provox Vega. These results will facilitate the design of prospective studies to assess reasons for variations in device life between patients and device types.
28 December 2019 in Psychosomatics
1 November 2016 in Oral Oncology